Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-08-22
2006-08-22
Duffy, Patricia A. (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S007220, C435S975000
Reexamination Certificate
active
07094879
ABSTRACT:
The present invention relates to a genetically engineered P30 antigen and a combination or mixture of antigens (e.g., the genetically engineered P30 antigen and P35) that may be used in the detection of IgM and/or IgG antibodies toToxoplasma gondii.Furthermore, the present invention also relates to methods of using this genetically engineered P30 antigen and combination of antigens, antibodies raised against this genetically engineered P30 antigen and combination of antigens, as well as kits and vaccines containing the genetically engineered P30 antigen and antigens present in the combination.
REFERENCES:
patent: 6329157 (2001-12-01), Maine et al.
patent: 6372443 (2002-04-01), Jacobs et al.
patent: 99/61906 (1999-12-01), None
Gerhold et al.[BioEssays, vol. 18, No. 12, pp. 973-981 (1996)].
Wells et al.Journal of Leukocyte Biology, vol. 61, No. 5, pp. 545-550 (1997).
Russell et al.Journal of Molecular Biology, vol. 244, pp. 332-350 (1994).
Remington, J.S., et al.,Infectious Diseases of the Fetus and Newborn Infant, Fourth Edition, “Toxoplasmosis”, J.S. Remington and J.O. Klein, Eds., pp. 140-267, Saunders, Philadelphia (1995).
Sabin, A.B. et al.,Science, “Dyes as Microchemical Indicators of a New Immunity Phenomenon Affecting a Protozoon parasiste (Toxoplasma)”, vol. 108, pp. 660-663 (1948).
Jacobs, L., et al.,J. Parasitol, “A Hemagglutination Test for Toxoplasmosis”, vol. 43, pp. 308-314 (1957).
Walton, B.C. et al.,Am. J. Trop. Med. Hyg., “Comparison of the Indirect Fluorescent Antibody Test and Methylene Blue Dye Test for Detection of Antibodies to Toxoplasma Gondii”, vol. 15, pp. 149-152 (1966).
Naot, Y. et al.,J. Infect. Dis., An Enzyme-Linked Immunosorbent Assay for Detection of IgM Antibodies to Toxoplasma Gondii: Use for Diagnosis of Acute Acquired Toxoplasmosis, 142, pp. 757-766 (1980).
Prince, et al.,Mol. Biochem. Parasito, “Cloning Expression, and cDNA Sequence of Surface Antigen P22 from Toxoplasma Gondii”, vol. 43, pp. 97-106 (1990).
Cesbron-Delauw, et al.,Proc. Nat. Acad. Sci., “Molecular characterization of a 23-Kilodalton Major Antigen Secreted by Toxoplasma Gondii”, vol. 86, pp. 7537-7541 (1989).
Johnson, et al.,Gene, “Cloning of Toxoplasma Gondii Gene Fragments Encoding Diagnostic Antigens”, vol. 99, pp. 127-132 (1991).
Prince, et al.,Mol. Biochem. Parasiotol, “Cloning of cDNAs Encloding a 28 Kilodalton Antigen of Toxoplasma Gondii”, vol. 34, pp. 3-13 (1989).
Bonhomme, et al.,J. Histochem. Cytochem, “Quantitative Immunolocalization of a P29 Protein (GRA7), a New Antigen of Toxoplasma Gondii”, vol. 46, pp. 1411-1421 (1998).
Burg, et al.,J. Immunol., “Molecular Analysis of the Gen Encoding the major Surave Antigen of Toxoplasma Gondii”, vol. 141, pp. 3584-3591 (1998).
Mevelec, et al.,Mol. Biochem. Parasitol., “Molecular Cloning of GRA4, a Toxoplasma Gondii Dense Granule Protein, Recongnized by Mucosal IgA Antibodies”, vol. 56, pp. 227-238 (1992).
Saavedra, et al.,J. Immunol., “Human T Cell Clone Identifies A Potentially Protective 54-kDa Protein Antigen of Toxoplasma Gondii Cloned and Expressed inExcherichia coli”, vol. 147, pp. 1975-1982 (1991).
Safford, et al.,J. Clin. Pathol., “Automated Microparticle Enzyme Immunoassays for IgG and IgM Antibodies to Toxoplasma Gondii”, 44:238-242 (1991).
Kapust and Waugh,Protein Science, “Escherichia coliMaltose-Binding Protein is Uncommonly Effective at Promoting the Solubility of Polypeptides To Which It Is Fused”, 8, 1668-1674 (1991).
Robinson, et al.,J. Clin. Microbiol., “Analysis of the Humoral Response to the Flagellin Protein of Borrelia Burgdorferi: Cloning of Regions Capable of Differentiating Lyme Disease from Syphilis”, 31:629-635 (1993).
Velge-Roussel, et al.,Molec. Biochem. Parasitol, “Epitopic Anlaysis of the Toxoplasma Gondii Major Surface Antigen SAG1”, 66:31-38 (1994).
Desomonts, G. and Remington, J.S.,J. Clin. Microbiol., “Direct Agglutination Test for Diagnosis of Toxoplasma Infection: Method for Increasing Sensitivity and Specificity”, 11:562-568 (1980).
Pouletty, et al.J. Immunol. Methods, “An Anti-human γ Chain Monoclonal Antibody: Use for Detection of IgM Antibodies to Toxoplasma Gondii by Reverse Immunosorbent Assay”, 76:289-298 (1985).
Zweig, HM,Clin. Chem., “Receiver-Operating Characteristic (ROC) Plots: A Fundamental Evaluation Tool in Clinical Medicine”, 39:561-577 (1993).
New England Biolabs, Inc. 1998/1999 Catalog, pp. 136-137.
Bliese Timothy R.
Ginsburg Sanford R.
Maine Gregory T.
Patel Chandu B.
Abbott Laboratories
Becker Cheryl L.
Duffy Patricia A.
LandOfFree
Genetically engineered P30 antigen, improved antigen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetically engineered P30 antigen, improved antigen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetically engineered P30 antigen, improved antigen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3701349